Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT

Bone marrow toxicity in advanced prostate cancer patients who receive [177Lu]Lu-PSMA-617 is a well-known concern. In early stage patients; e.g. low volume metastatic hormone sensitive prostate cancer (mHSPC) pati...

Source: EJNMMI Physics - April 3, 2024 Category: Radiology Authors: Dagmar Grob, Bastiaan M. Priv é, Constantijn H. J. Muselaers, Niven Mehra, James Nagarajah, Mark W. Konijnenberg and Steffie M. B. Peters Tags: Original research Source Type: research